Apolipoprotein CIII ELISA Assay
The Apolipoprotein CIII ELISA Assay is For Research Use Only
Size: 1×96 wells
Sensitivity: 50 pg/ml
Dynamic Range: 31.3-2000 pg/ml
Incubation Time: 4.5 hours
Sample Type: Serum, Plasma, or other biological fluids
Sample Size: 100 µL
Alternative Names: Human ApoCIII
SAMPLE COLLECTION & STORAGE INFORMATION
The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.
Serum- Use a serum separator tube (SST) and allow samples to clot for few minutes before centrifugation for 10 minutes at 1000 x g at 4°C. Collect serum and assay immediately or aliquot and store samples at -80°C up to 3 months. Avoid repeated freeze-thaw cycles.
Plasma – Collect plasma using EDTA or heparin as an anticoagulant at 4°C. Centrifuge for 10 minutes at 1000 x g at 4°C within 30 minutes of collection. Assay immediately or aliquot and store samples at-80°C up to 3 months. Avoid repeated freeze-thaw cycles.
Other Biological Fluids – Centrifuge samples for 10 minutes at 1000 g at 4°C. Assay immediately or aliquot and store samples at-80°C up to 3 months. Avoid repeated freeze-thaw cycles.
Apolipoprotein CIII (ApoCIII) is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. [provided by RefSeq, Jul 2008] Apolipoprotein CIII (ApoCIII) is a component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors.